Recordati buys Farma-Projekt in Poland
This article was originally published in Scrip
The Italian pharmaceutical company Recordati has agreed to pay PLN 71 million ($21 million) to acquire Farma-Projekt, a Polish firm that sells cardiovascular and urological products (also key areas for Recordati) and dietary supplements. It employs around 135 people, with 84 in sales and marketing, and had sales in 2011 of about PLN 47 million.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.